Athera Biotechnologies AB   Report issue

For profit Phase 2
Founded: Stockholm Sweden (2005)

Organization Overview

First Clinical Trial
2017
NCT03320265
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Athera Biotechnologies AB